Acute antithrombotic treatment of ischemic stroke

Current Vascular Pharmacology

Volumn 12, Issue 3, 2014, Pages 353-364

  Alderazi, Yazan J ^a   Grotta, James C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Acute ischemic stroke; Anticoagulants; Antiplatelets; Argatroban; Cerebral venous sinus thrombosis; Glycoprotein GPIIb IIIa inhibitors; Thrombolytics; Tissue plasminogen activator

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ARGATROBAN; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; DESMOTEPLASE; DIPYRIDAMOLE; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; MATRIX METALLOPROTEINASE; PROUROKINASE; RETEPLASE; TENECTEPLASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY OCCLUSION; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN CIRCULATION; BRAIN ISCHEMIA; BRAIN PERFUSION; CARDIOEMBOLIC STROKE; CEREBRAL SINUS THROMBOSIS; CHADS2 SCORE; COLLATERAL CIRCULATION; DISEASE COURSE; HEART ATRIUM FIBRILLATION; HUMAN; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANKIN SCALE; THROMBOEMBOLISM; THROMBOSIS; THROMBUS; ACUTE DISEASE; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; METABOLISM; STROKE;

ACUTE DISEASE; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; STROKE;

EID: 84922392453     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111203140517190731     Document Type: Article

References (87)

1. [1] Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
2. [2] Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke 2001; 32: 1732-8.
3. [3] Nemoto EM, Yonas H, Chang Y. Stages and thresholds of hemodynamic failure. Stroke 2003; 34: 2-3.
4. [4] Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009; 40: 2276-93.
5. [5] Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981; 54: 773-82.
6. [6] Baird AE, Benfield A, Schlaug G, et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 1997; 41: 581-9.
7. [7] White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation 2005; 111: 1327-31.
8. [8] Romero JR, Pikula A, Nguyen TN, et al. Cerebral collateral circulation in carotid artery disease. Curr Cardiol Rev 2009; 5: 279-88.
9. [9] Liebeskind DS. Collateral circulation. Stroke 2003; 34: 2279-84.
10. [10] Lok J, Gupta P, Guo S, et al. Cell-cell signaling in the neurovascular unit. Neurochem Res 2007; 32: 2032-45.
11. [11] Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004; 35: 2659-61.
12. [12] Montaner J, Molina CA, Monasterio J, et al. Matrix metallopro-teinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
13. [13] Tanswell P, Tebbe U, Neuhaus KL, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071-5.
14. [14] Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
15. [15] Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004; 61: 1066-70.
16. [16] Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-29.
17. [17] Saver JL, Gornbein J, Grotta J, et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3-to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke 2009; 40: 2433-7.
18. [18] Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703.
19. [19] Maiser SJ, Georgiadis AL, Suri MF, et al. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis. Int J Stroke 2011; 6: 25-32.
20. [20] Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3-to 4.5-hour time window for acute ischemic stroke. Stroke 2011; 42: 2257-62.
21. [21] Massachusetts General Hospital. MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients. Massachusetts General Hospital In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Oct 17] Available from: http://clinicaltrials.gov/ct2/show/NCT01282242 NLM Identifier:NCT01282242.
22. [22] Baranes D, Lederfein D, Huang YY, et al. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 1998; 21: 813-25.
23. [23] Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33: 831-6.
24. [24] Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-4.
25. [25] Kilic E, Hermann DM, Hossmann KA. Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. Neuroreport 1999; 10: 107-11.
26. [26] Schleuning WD. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis 2001; 31: 118-22.
27. [27] Toschi L, Bringmann P, Petri T, Donner P, Schleuning WD. Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators. Eur J Biochem 1998; 252: 108-12.
28. [28] Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34: 537-43.
29. [29] H Lundbeck, A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke (DIAS-3). H. Lundbeck A/S In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2011 Oct 17] Available from: http://clinicaltrials.gov/ct2/show/NCT00790920 NLM Identifier: NCT00790920.
30. [30] H. Lundbeck, A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke (DIAS-4). H. Lundbeck A/S In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2011 Oct 17] Available from: http://clinicaltrials.gov/ct2/show/ NCT00856661 NLM Identifier: NCT00856661.
31. [31] Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 141-50.
32. [32] Haley EC Jr, Thompson JL, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010; 41: 707-11.
33. [33] Parsons MW, Miteff F, Bateman GA, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009; 72: 915-21.
34. [34] Cornu C, Boutitie F, Candelise L, et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis: The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000; 31: 1555-60.
35. [35] Levy DE, del Zoppo GJ, Demaerschalk BM, et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke 2009; 40: 3796-803.
36. [36] Ogawa A, Mori E, Minematsu K, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007; 38: 2633-9.
37. [37] Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Jama 1999; 282: 2003-11.
38. [38] Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001; 49: 41-8; discussion 48-50.
39. [39] Qureshi AI, Harris-Lane P, Kirmani JF, et al. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study. Neurosurgery 2006; 59: 789-96.
40. [40] Broderick JP, Palesch YY, Demchuk AM, et al. Interventional Management of Stroke (IMS) III Investigators. Endovascular ther- apy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013; 368(10): 893-903.
41. [41] Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35: 904-11.
42. [42] The Interventional Management of Stroke (IMS) II Study. Stroke 2007; 38: 2127-35.
43. [43] Khatri P, Abruzzo T, Yeatts SD, et al. Good clinical outcome after ischemic stroke with successful revascularization is time- dependent. Neurology 2009; 73: 1066-72.
44. [44] The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-81.
45. [45] CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349: 1641-9.
46. [46] Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
47. [47] Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-9.
48. [48] Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.
49. [49] Shinohara Y, Katayama Y, ` Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-68.
50. [50] Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005; 36: 880-90.
51. [51] Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39: 87-99.
52. [52] Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008; 39: 3268-76.
53. [53] University of Cincinnati. The "Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke- Enhanced Regimen" (CLEAR-ER Stroke Trial). University of Cincinnati In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2011 Oct 17] Available from: http://clinicaltrials.gov/show/NCT00894803NLM Identifier: NCT00894803.
54. [54] Siebler M, Hennerici MG, Schneider D, et al. Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke 2011; 42: 2388-92.
55. [55] Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353: 1028-40.
56. [56] Caplan LR. Resolved: Heparin may be useful in selected patients with brain ischemia. Stroke 2003; 34: 230-1.
57. [57] Duke RJ, Bloch RF, Turpie AG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986; 105: 825-8.
58. [58] Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38: 423-30.
59. [59] Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205-10.
60. [60] Diener HC, Ringelstein EB, von Kummer R, et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke 2001; 32: 22-9.
61. [61] Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358: 702-10.
62. [62] Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998; 279: 1265-72.
63. [63] Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997; 23: 531-4.
64. [64] Barreto AD, Alexandrov AV, Lyden P, et al. The Argatroban and Tissue-Type Plasminogen Activator Stroke Study: Final Results of a Pilot Safety Study. Stroke 2012; 43: 770-5.
65. [65] The University of Texas Health Science Center, Houston. ARTSS-2: A Pilot, Phase IIb, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke. The University of Texas Health Science Center, Houston In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2012 Jan 23] Available from: http://clinicaltrials.gov/ct2/show/NCT 01464788NLM Identifier: NCT01464788.
66. [66] Ferro JM, Canhao P, Stam J, Bousser MG. Barinagarrementeria F Prognosis of cerebral vein and dural sinus thrombosis: results of the International study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-70.
67. [67] Ferro M, Lopes MG, Rosas MJ, Ferro MA, Fontes J. Long-term prognosis of cerebral vein and dural sinus thrombosis. results of the VENOPORT study. Cerebrovasc Dis 2002; 13: 272-8.
68. [68] Einhaupl KM, Villringer A, Meister W, et al, Heparin treatment in sinus venous thrombosis. Lancet 1991; 338: 597-600.
69. [69] de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30: 484-8.
70. [70] Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev 2011: CD002005.
71. [71] Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6: 162-70.
72. [72] Einhaupl K, Stam J, Bousser MG, et al. EFNS guideline on thetreat ment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17: 1229-35.
73. [73] Stam J, Majoie CB, van Delden OM, van Lienden KP, Reekers JA. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study. Stroke 2008; 39: 1487-90.
74. [74] Lyden PD, Meyer BC, Hemmen TM, Rapp KS. An ethical hierarchy for decision making during medical emergencies. Ann Neurol 2010; 67: 434-40.
75. [75] Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from t-PA therapy? An analysis of patient eligibility. Neurology 2001; 56: 1015-20.
76. [76] Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993-1003.
77. [77] Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-16.
78. [78] Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
79. [79] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
80. [80] Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
81. [81] Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-92.
82. [82] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
83. [83] Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945-8.
84. [84] Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59: 862-7.
85. [85] The University of Texas Health Science Center, Houston. Safety of Intravenous Thrombolysis for Wake-up Stroke. The University of Texas Health Science Center, Houston In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2011 Oct 17] Available from: http://clinicaltrials.gov/ ct2/show/NCT01183533 NLM Identifier: NCT01183533.
86. [86] Qureshi AI, Siddiqui AM, Kim SH, et al. Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol 2004; 25: 322-8.
87. [87] Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-80.